ExomiR‐375 has been reported to promote bone marrow metastases in patients with neuroblastoma (NB) (Colletti et al., 2020) by downregulating YAP1 levels which enhance osteogenic differentiation of mesenchymal stromal cells (Colletti et al., 2020). Here, YAP1 is linked to neuroblastoma.